Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) are rare genetically heterogeneous hematologic diseases associated with older age and a poor prognosis. If the disease progresses into acute myeloid leukemia (AML), it is often refractory to treatment. To gain insight into genetic alterations associated with disease progression, we used whole exome sequencing and single nucleotide polymorphism arrays to characterize the bone marrow and blood samples from a 39-year-old woman at MDS/MPN-U diagnosis and at AML progression, in which routine genetic diagnostics had not identified any genetic alterations. Our data revealed the presence of a partial tandem duplication of the MLL gene as the only detectable copy number change and 11 non-silent somatic mutations, including DNMT3A R882H and NRAS G13D. All somatic lesions were present both at initial MDS/MPN-U diagnosis and at AML presentation at similar mutant allele frequencies. The patient has since had two extramedullary relapses and is at high risk of a future bone marrow relapse. A directed ex vivo drug sensitivity analysis showed that the patient´s AML cells are sensitive to, e.g., the MEK inhibitor trametinib and the proteasome inhibitor bortezomib, indicating that she may benefit from treatment with these drugs.
INTRODUCTION
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/ MPN-U) are rare heterogeneous diseases associated with older age (≥60 years), an inferior overall survival of 12.4-21.8 months, and progression to acute myeloid leukemia (AML) in 23-54% of the cases (Cannella et al., 2008; DiNardo et al., 2014; Wang et al., 2014) . MDS/MPN-U belongs to the MDS/MPN World Health Organization category, a group of myeloid neoplasms that have both myelodysplastic and myeloproliferative features at diagnosis. This category also comprises atypical chronic myeloid leukemia, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, and refractory anemia with ring sideroblasts and thrombocytosis (Vardiman et al., 2009) . Of these, MDS/MPN-U is the least well characterized group and no specific genetic alterations have been found; instead they share many alterations with myeloid disorders, including isolated trisomy 8 and recurrent mutations in, e.g., DNMT3A, JAK2, KRAS/NRAS, RUNX1, and SETBP1 (Ernst et al., 2010; Meggendorfer et al., 2013; DiNardo et al., 2014; Wang et al., 2014) . Recently, mutations in ASXL1, TET2, and U2AF1 were shown to occur at high frequencies in MDS/MPN-U, with mutations in U2AF1 being enriched in this subtype (Meggendorfer et al., 2014) .
Few studies are available where genetic alterations occurring during the progression of MDS/MPN-U into AML have been studied (Hahm et al., 2015) . Herein, we describe a unique case of an MDS/MPN-U, in a 39-year-old woman, that after two months of diagnosis progressed into AML. Using whole exome sequencing and high-resolution single nucleotide polymorphism (SNP) arrays, we identified a partial tandem duplication of the MLL gene (also called KMT2A) as the only copy number alteration and the presence of 11 validated somatic non-silent mutations, including DNMT3A R882H and NRAS G13D, all of which were present both at initial MDS/MPN-U diagnosis as well as at AML presentation. Importantly, we further show that the leukemic cells upon progression into AML were responsive ex vivo to, e.g., the MEK inhibitor tramatenib and the proteasome inhibitor bortezomib.
MATERIALS AND METHODS

Patient History
A 39-year-old woman presented with an atypical bone marrow disease with pronounced leukocytosis, neutrophilia, monocytosis, considerable cervical lymphadenopathy, and enlarged submandibular glands. A lymph node biopsy revealed a disrupted architecture with confluent abnormal sheets of highly proliferating left-shifted myeloid cells including dysplastic granulocytes and monocytoid cells (Supplementary Figs. S1A and B and S2) and a low frequency of myeloid blasts, promonocytes, and monocytes (2%, 1%, and 4%, respectively, Supplementary Fig. S3A ). The tumor masses were evaluated by a pathologist and determined to be an MDS/MPN-U. Analyses of the bone marrow recapitulated the morphological and immunophenotypic findings of the lymph node, but with a lower frequency of abnormal myeloid blast cells (0.1%; Supplementary Figs. S1C and S3B).
Clinical genetic diagnostics revealed a normal female karyotype and lack of BCR-ABL1, FIP1L1-PDGFRA, and JAK2 mutations.
The MDS/MPN-U progressed to AML two months after initial diagnosis, with elevated numbers of abnormal promonocytes and monocytes (19% and 23%, respectively; Supplementary Fig. S3C ). Except for the loss of CD56 on the promonocyte-like cells in the AML specimen (data not shown), the phenotype of the AML cells was similar to that of the MDS/MPN-U cells (Supplementary Figs. S1D and S3A-C). An allogeneic bone marrow transplantation was performed in first complete remission, but the patient has since had two extramedullary relapses with infiltrating immature myeloid cells ( Supplementary Fig. S4 and Supporting Information for full patient history).
Patient Material
Bone marrow (BM) was collected at the time of presentation, and three months later when the patient had developed AML, a peripheral blood (PB) sample was collected. As constitutional DNA (germline control) for the genomic analyses, a skin biopsy was taken at first complete remission.
DNA Extraction
Mononucleated cells (MNCs) were purified from PB and BM with lymphoprep (AXIS-SHIELD, Oslo, Norway), and DNA and RNA were extracted. DNA from BM, PB, and cultured cells from the skin sample was extracted with the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany). Total RNA was extracted from BM and PB with the Trizol Reagent (Life Technologies Corp., Carlsbad, CA). The DNA quantity was assessed with the Qubit Fluorometer (Life Technologies, Paisley, UK). The RNA quantity and quality was assessed by the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA) and the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA) respectively.
Histopathology and Immunohistochemistry
Embedment, sectioning, hematoxylin-eosin staining, and immunohistochemistry of biopsies were performed according to standard clinical protocols.
The Ki67 antibody (Dakos, Stockholm, Sweden) was used to estimate proliferation.
Immunophenotypic Analysis by Flow Cytometry
Sample preparation and staining were performed according to standard clinical protocols. Antibodies were purchased from BD (Becton, Dickinson and Company, Franklin Lakes, NJ). Samples were analyzed on a BC Navios (Beckman Coulter, Miami, FL).
High Resolution Genomic Profiling Using SNP Array
The SNP array analysis was performed using the 2.7M. CytoScan HD Array 
Exome Capture and Sequencing
Exome capture and sequencing of the MDS/MPN-U, AML, and germline samples were performed by Ambry Genetics (Aliso Viejo, CA). In brief, whole exome target enrichment was performed using the VCRome kit (Roche NimbleGen, Madison, WI). Library preparation was prepared using kits and reagents from Illumina (Illumina, San Diego, CA), and 100 bp paired end sequencing was performed using the Illumina HiSeq platform.
Validation of the MLL-PTD
The MLL-PTD was validated by RT-PCR using the primer combinations 5.3+3.1c/654c and 5.3+4.1R as described (Caligiuri et al., 1996) . Briefly, 2.5 µg RNA was converted into cDNA using standard protocols. The RT-PCR reaction was performed using the Platinum Taq DNA Polymerase kit (Life Technologies) according to the manufacturer´s instructions using the following primers: 5.3 (5´-GGAAGTCAAGCAAGCAGGTC-3´),
for 35 cycles (95°C, 1 min; 53°C, 1 min; 72°C, 1 min) (Caligiuri et al., 1996) . Products were analyzed by agarose gel electrophoresis, purified using the QIAquick Gel Extraction Kit (Qiagen), followed by Sanger sequencing using the BigDye Sequencing primers used: 5.3, 3.1c/654c and 4.1R (see above), 6.1 (5´-GTCCAGAGCAGAGCAAACAG-3´), 3.2c/400c (5´-ACACAGATGGATCTGAGAGG-3´), and 4.2R (5´-GGAGCAAGAGGTTCAGCATC-3´) (Caligiuri et al., 1996) .
Validation of Somatic Mutations
For validation, putative non-silent mutations had to fulfill either of the following criteria; the putative mutation was present in both the MDS/MPN-U and the AML sample regardless of mutant allele frequency, or the gene was listed in the Cancer Gene Consensus fragmented to approximately 300 bp and adapter sequences were added simultaneously using the Nextera XT transposome. Amplicons were then indexed and amplified using PCR and subsequently purified using Ampure XP beads. Sample libraries were pooled and sequencing was prepared according to the MiSeq protocol as described by the manufacturer. In addition, a selected set of 16 putative variants with a mutant allele frequency of ≥20% from above was subjected to Sanger sequencing (GATC Biotech AG, Konstanz, Germany).
Sequencing Data Analysis
Paired end reads were aligned to UCSC build Hg19 using the BWA (version 0.6.2) aligner (Li and Durbin, 2009) (Saunders et al., 2012) and annotated using Annovar (Wang et al., 2010) . Presence of reads in the germline sample that cover the mutant allele is considered a germline variant. The position of a putative mutation is based on Hg19 and the effect at the protein level of a putative mutation was investigated using SIFT or Polyphen (Ng and Henikoff, 2003; Adzhubei et al., 2010) .
Cell Culture
Viably frozen PB MNCs collected at AML diagnosis were thawed in IMDM 
RESULTS
Genomic Analyses at MDS/MPN-U Diagnosis and Progression to AML
To determine the copy number alterations present at AML presentation, highresolution SNP array analysis was performed, which revealed the presence of an MLL-PTD as the only detectable genomic imbalance ( Supplementary Fig. S5A ). Validation of the rearrangement at the RNA level by PCR followed by Sanger sequencing revealed two variants corresponding to an in-frame duplication of MLL exons 2-8 and an out-of-frame duplication of exons 5-8 and that the MLL-PTD was present already at diagnosis of MDS/MPN-U ( Supplementary Fig. S5B-D) .
The number of coding gene mutations at MDS/MPN-U and at AML presentation was determined by whole exome sequencing ( Supplementary Table S1 ). DNA from cultured cells from a skin biopsy was used as constitutional DNA (referred to as germline sample). Eleven validated somatic non-silent mutations, including DNMT3A R882H
and NRAS G13D ( Supplementary Fig. S6A and B) , were identified, all of which were present both at initial MDS/MPN-U diagnosis as well as at AML presentation ( Table 1 ). The remaining mutations are not reported in COSMIC, but mutations at other sites in these genes have previously been seen in AML or in other cancer forms (Cancer Genome Atlas Research Network, 2013). The mutant allele frequencies of the identified mutations indicated that they were present in the dominant clone both at MDS/MPN-U diagnosis and at AML presentation (Table 1) .
Directed Drug Assay Indicates Potent Response to MEK-and Proteasome Inhibition
We next investigated if we could utilize the genetic information obtained from the genome wide analyses to identify alternative treatment modalities for the patient using US Food and Drug administration (FDA) approved compounds. Six different drugs were chosen based on the literature and previous treatment of the patient; the chemotherapeutic drugs ara-C and daunorubicin, the proteasome inhibitor bortezomib, the histone deacetylate agent vorinostat, the hypomethylating drug decitabine, and the MEK inhibitor trametenib. We also included the AML cell lines THP-1 (expressing MLL-MLLT3) and KG-1 (expressing FGFR1OP2-FGFR1), both of which harbor mutant NRAS (Janssen et al., 1987) .
The analysis revealed that the AML cells were highly sensitive towards the MEK inhibitor trametinib (Fig. 2F ) and exhibited an IC50 close to that of the NRAS mutant cell line THP-1 (33 nM and 3 nM, respectively). In contrast, despite that KG-1 also has an NRAS mutation it was non-responsive towards trametenib. No marked difference in the sensitivity towards ara-C, daunorubicin, bortezomib, and vorinostat was seen among the samples ( Fig. 2A-D) . Finally, the AML cells were less sensitive towards decitabine as compared with KG-1 (IC50 of 1984 nM and 81 nM, respectively).
DISCUSSION
MPD/MDS-U is a rare group of hematopoietic diseases with a poor prognosis that progress to AML in 23-54% (Cannella et al., 2008; DiNardo et al., 2014; Wang et al., 2014) . To gain insight into the genetic changes associated with evolution to AML, we determined the coding genetic lesions of hematologic samples from a single patient at MPD/MDS-U diagnosis and at AML presentation. Our analyses identified an MLL-PTD as well as 11 additional non-silent mutations, including mutations in NRAS and DNMT3A. An MLL-PTD is present in approximately 8% of AML cases with a normal karyotype and is typically considered an adverse prognostic factor (Caligiuri et al., 1998; Döhner et al., 2002; Schlenk et al., 2008) . However, younger patients with an MLL-PTD treated with an intensified consolidation therapy including autologous peripheral stem cell transplantation had similar outcomes to that of AML patients with normal karyotype lacking MLL-PTD,
showing that intensified treatment may modulate the historically poor outcome of this leukemia subtype (Whitman et al., 2007) .
Mutations in DNMT3A were first identified as part of a whole genome sequencing effort of an AML patient with a normal karyotype; mutations in this gene were highly recurrent in an extended cohort, in particular among patients with a cytogenetic profile associated with an intermediate risk (34%), including patients with a normal cytogenetics (37%) (Ley et al., 2010) . Although mutations are found across the entire DNMT3A gene, the R882 codon, identified also in our patient, is a known hot spot, with R822H being the most common substitution ( Supplementary Fig. S6A ). Several studies have shown that mutations in DNMT3A correlate with an inferior outcome (Ley et al., 2010; Thol et al., 2011; Yan et al., 2011) ; however, the largest study to date could not verify this; only among cytogenetically normal patients in the unfavorable subgroup, as defined by the European LeukemiaNet, had the presence of a R882 mutation a moderate negative prognostic effect (Gaidzik et al., 2013) .
DNMT3A mutations in secondary AML have been described to be present in the corresponding antecedent MDS or MPN, in a series of ten patients, suggestive of an early event (Fried et al., 2012) . In addition to the DNMT3A mutation, our patient had an NRAS G13D; NRAS mutations occur in around 10-13% of patients with AML but do not confer any significant prognostic impact (Bacher et al., 2006; Schlenk et al., 2008) .
All mutations identified at initial MDS/MPN-U diagnosis were present at AML presentation and no additional mutations were identified in the AML specimen. Furthermore, at the level of detection of our analysis, the mutant allele frequencies indicated that all mutations were present in the dominant leukemia clone both at initial MDS/MPN-U diagnosis as well as at AML presentation. Thus, it appears as if all of the mutations needed for AML were there, already two months before the AML diagnosis.
Despite a good initial response to chemotherapy, the patient experienced two extramedullary relapses with infiltrating immature myeloid cells (Supporting Information). To identify alternative treatment modalities that could be used at a future potential bone marrow relapse, we investigated the response of her AML cells ex vivo to a selected set of drugs.
Because it is difficult to culture primary AML cells ex vivo without spontaneous differentiation (Mayani et al., 2009) , we implemented the recently optimized culture conditions proposed to maintain AML self-renewal, mainly by antagonizing the aryl hydrocarbon receptor pathway (Pabst et al., 2014) .
We found that that the patient´s AML cells were sensitive towards inhibition of MEK ex vivo, suggesting a potential clinical benefit of this treatment. The AML cells had an IC50 for trametinib similar to that of RAS mutant primary MLL-rearranged AML samples (Lavallée et al., 2015) . Likewise, the MLL positive NRAS-dependent cell line THP-1 (Burgess et al., 2014) proved highly sensitive, whereas KG-1 was non-responsive despite that fact that it harbors mutant NRAS (Long et al., 2014) . Trametinib is a potent MEK inhibitor approved for BRAF mutant unresectable or metastatic melanoma, and has been proposed to have an increased efficacy in NRAS mutant AML (Burgess et al., 2014; Lavallée et al., 2015) and is in clinical trial for AML with mutant NRAS (clinicaltrials.gov identifier NCT01907815). Our data further demonstrate that the AML cells, as well as THP-1 and KG-1, were sensitive towards bortezomib (Horton et al., 2006; Oerlemans et al., 2008) . Bortezomib in combination with vorinostat have shown high efficacy in primary infant MLL-rearranged acute lymphoblastic leukemia drug assays (Koss et al., 2014) and are in clinical trial as a combinatorial therapy for younger patients with leukemia (clinicaltrials.gov identifier NCT02419755). Similar to the ara-C resistant cell line THP-1 (Ge et al., 2004) , the AML cells had relatively high IC50 for this drug. Finally, decitabine is approved for treatment of high-risk MDS (Im et al., 2014) and may improve the complete remission rates in AML (Metzeler et al., 2012) and MDS patients (Traina et al., 2014) with DNMT3A mutations.
Notably, in our analyses, the AML sample was the least sensitive sample towards decitabine despite the fact that it harbors a DNMT3A mutation; the DNMT3A wild-type cell line KG-1 was more sensitive (Tiacci et al., 2012) .
Taken together, genomic characterization using high resolution SNP array profiling and whole exome sequencing of the leukemic specimens from a woman presenting with MDS/MPN-U revealed the presence of twelve genetic lesions including a partial tandem duplication of MLL and missense mutations in DNMT3A and NRAS. The results of the extended genetic analysis performed as part of this study can be used to confirm and monitor a possible bone marrow relapse, which would be helpful to make a decision on the need of systemic therapy. Her disease course together with her high-risk genetic lesions suggests a poor prognosis and that she may benefit from alternative treatment modalities, potentially by targeting the RAS signaling pathway using, e.g., the MEK inhibitor trametinib or by proteasome inhibition through bortezomib.
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Supporting Information for
Patient history
A 39-year-old woman presented with an atypical bone marrow disease in March 2012. One year before initial presentation, she experienced joint aches and borderline anemia (Hb of 116 g/l); six months before initial diagnosis, she became very tired and two months before she quickly lost 13 kg of weight. At diagnosis, she had pronounced leukocytosis, with increased neutrophils, monocytes, and appearance of immature blood cells including blasts.
Her peripheral blood cell counts at diagnosis were: white blood cells 45 x 10 9 /l (72% neutrophils, 7% monocytes, 1.8% promyelocytes, 1.8% metamyelocytes, 0.4% myelocytes, and (0.9% blasts), platelets 61 x 10 9 /l, and Hb 68 g/l. She presented with cervical lymphadenopathy and a soft tissue mass in the submandibular gland. The tumor masses were evaluated by a pathologist and determined to be a myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U). A bone marrow aspirate showed 1.5% promonocytes (CD117 + /CD33 + /CD34 -/HLA -DR + /CD135 + /CD133 + ) and 4.3% abnormal monocytes (CD56 + /CD123 + /CD135 + ).
Clinical genetic diagnostics revealed a normal female karyotype and lack of the t(9;22)(q34;q11)/BCR-ABL1 fusion gene, del(4)(q12)/FIP1L1-PDGFRA rearrangement and JAK2 mutations (codon V617 and exon 12 investigated). Treatment was started with hydroxyurea and she received multiple blood transfusions. Two months after initial presentation (in May) she developed a further increase in leukocytes (90.7 x 10 9 /l), monocytes (16.1 x 10 9 /l), and blast cells (4.8 x 10 9 /l), fever, and gingivitis. A bone marrow aspirate showed high cellularity, 24% of myeloid blast cells, and a high frequency of atypical monocytes and eosinophils. The immunophenotype was similar to the initial bone marrow examination with 19.4% promonocytelike cells CD117 + /CD33 + /CD34 -/HLA -DR + /CD135 + /CD133 +and 22.7% abnormal monocytes (CD56 + /CD123 + /CD135 + ); AML was diagnosed. Induction and consolidation therapy was given with daunorubicin and cytarabine.
She subsequently underwent allogeneic bone marrow transplantation in first complete remission in September 2012 and was allografted with cells from an unrelated donor after a myeloablative conditioning with total body irradiation and high dose cyclophosphamide. The patient developed a skin graft-versus-host-disease that was treated with steroids.
Twenty-one months after initial MDS/MPN-U diagnosis, in December 2013, the patient relapsed with a local tumor mass in her right breast and underwent local radiation therapy. Pathological evaluation revealed infiltration of immature myeloid cells (MPO + , CD117 + , CD68 + ). At that time, no leukemic cells could be detected in the bone marrow.
Twenty-one months after her first relapse, she developed a second extramedullary relapse with a parasternal soft tissue tumor mass, and was treated with local radiation therapy.
